...
首页> 外文期刊>Angewandte Chemie >Ruthenium-Containing Linear Helicates and Mesocates with Tuneable p53-Selective Cytotoxicity in Colorectal Cancer Cells
【24h】

Ruthenium-Containing Linear Helicates and Mesocates with Tuneable p53-Selective Cytotoxicity in Colorectal Cancer Cells

机译:含钌的线性螺旋和中胞质,具有可调性P53选择性细胞毒性在结肠直肠癌细胞中

获取原文
获取原文并翻译 | 示例
           

摘要

The ligands L-1 and L-2 both form separable dinuclear double-stranded helicate and mesocate complexes with Ru-II. In contrast to clinically approved platinates, the helicate isomer of [Ru-2(L-1)(2)](4+) was preferentially cytotoxic to isogenic cells (HCT116 p53(-/-)), which lack the critical tumour suppressor gene. The mesocate isomer shows the reverse selectivity, with the achiral isomer being preferentially cytotoxic towards HCT116 p53(+/+). Other structurally similar Ru-II-containing dinuclear complexes showed very little cytotoxic activity. This study demonstrates that alterations in ligand or isomer can have profound effects on cytotoxicity towards cancer cells of different p53 status and suggests that selectivity can be tuned to either genotype. In the search for compounds that can target difficult-to-treat tumours that lack the p53 tumour suppressor gene, [Ru-2(L-1)(2)](4+) is a promising compound for further development.
机译:配体L-1和L-2均形成可分离的二核双链 - 用Ru-II的叠层复合物。 与临床批准的铂铂相比,[Ru-2(L-1)(2)](2)](4 +)的搭式异构体优先对等毒性细胞(HCT116 P53( - / - ))缺乏关键肿瘤抑制剂 基因。 中段异构体显示反向选择性,甲状腺异构体优先对HCT116 P53(+ / +)的细胞毒性。 其他结构上类似的含Ru-II的核络合物显示出很少的细胞毒性活性。 该研究表明,配体或异构体的改变可以对不同P53状态的癌细胞的细胞毒性产生深远的影响,并表明可以调整选择性。 在寻找可以针对缺乏p53肿瘤抑制基因的难以治疗肿瘤的化合物中,[Ru-2(L-1)(2)](4 +)是进一步发育的有希望的化合物。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号